1. Home
  2. Live Updates
  3. Her2 breast cancer

Live Breaking News & Updates on Her2 breast cancer

Stay informed with the latest breaking news from Her2 breast cancer on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Her2 breast cancer and stay connected to the pulse of your community

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

San-antonio , Texas , United-states , Saraa-hurvitz , Trastuzumab-emtansine , Primary-analysis , Double-blind-phase , Previously-treated , Metastatic-breast , Partnership-with , Antonio-breast-cancer-symposium

Subcutaneous Trastuzumab Induces Immune Function in HER2+ Breast Cancer

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer

Easter-cooperative-oncology-group , Her2-breast-cancer , Breast-cancer , Trastuzumab , Her2- , Residual-disease ,

Biomarker Data and Patient Preference Inform Perioperative Therapy Selection in Early HER2+ Breast Cancer

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.

Philadelphia , Pennsylvania , United-states , Maria-hafez , Sidney-kimmel-medical-college , Science-summit , Breast-cancer-clinical-research , Sidney-kimmel-cancer-center , Thomas-jefferson-university , Biomarker-data , Perioperative-therapy , Her2-breast-cancer

Imaging Scans for Assessing HER2-Positive Breast Cancer Progression and Treatment Response

Imaging scans provide an invaluable method of monitoring response to HER2-positive breast cancer treatment; frequency of imaging scans depends on individual patient response, symptoms, and the need to monitor for side effects such as interstitial lung disease.

Metastatic-breast-cancer-treatment , Positive-breast-cancer-progression , Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management , Breast-cancer-care

Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

Treatment for HER2-negative metastatic breast cancer depends on factors like hormone receptor status, with chemo/immunotherapy for PD-L1-positive triple negative disease, PARP inhibitors for BRCA mutations, and antibody-drug conjugates as options after first line therapy.

Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management , Breast-cancer-care , Breast-cancer-her2 , Her2-breast-cancer

Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

Metastatic-breast-cancer-treatment , Positive-metastatic-breast , Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management , Breast-cancer-care

Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.

Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management , Breast-cancer-care , Breast-cancer-her2 , Her2-breast-cancer

How HER2 Targeted Therapies Fight HER2-Positive Metastatic Breast Cancer

HER2-targeted therapies improve outcomes by shutting down growth signaling to cancer cells, targeted delivery of chemotherapy, or blocking intracellular signaling - all leveraging the HER2 receptor to better control metastatic breast cancer.

Metastatic-breast-cancer-treatment , Therapies-fight , Positive-metastatic-breast , Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management

Guideline-Recommended Treatments for HER2-Positive Metastatic Breast Cancer

Dr Sara M. Tolaney reviews the currently available treatment options for HER2-positive metastatic breast cancer and notes that many new HER2-targeting antibody-drug conjugates and bispecific antibodies are in development.

Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management , Breast-cancer-care , Breast-cancer-her2 , Her2-breast-cancer

Potential Severe Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

Patients on HER2-targeted therapies for HER2-positive metastatic breast cancer should be vigilant about potential side effects like heart toxicities and interstitial lung disease and should undergo regular heart function monitoring and lung scans to catch these side effects early.

Metastatic-breast-cancer-treatment , Severe-side-effects , Positive-metastatic-breast-cancer , Educated-patient-sound-bites , Breast-cancer , Sarah-tolaney-md , Patients-with-breast-cancer , Breast-cancer-patients , Breast-cancer-treatments , Breast-cancer-therapies , Breast-cancer-management